NANOBIOTIX Provides Business Update and Reports Full Year 20

Global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV expands worldwide potential of novel radioenhancer NBTXR3Prolonged survival in Study 102 reinforces...

Related Keywords

United States , Cambridge , Cambridgeshire , United Kingdom , France , Texas , Massachusetts , New York , Paris , France General , French , American , Brandon Owens , Kevin Gardner , Laurent Wormser , Bart Van Rhijn , Louis Kayitalire , Euronext , American Association For Cancer Research , Investor Relations Department , Johnson , Exchange Commission , Linkedin , Development Rd Expenses , Communications Department , Jjdc Inc , Given The Company , Twitter , Nasdaq , University Of Texas Md Anderson Cancer Center , European Society For Medical Oncology , Drug Administration , Janssen Pharmaceutica , Registration Document , Annual Report , Laurent Levy , Johnson Innovation , Subsequent Events , Pipeline Status , Chief Medical Officer , Advanced Head , Neck Squamous Cell Carcinoma , Local Control , Single Agent Activated , Annual Meeting , American Society , Radiation Oncology , European Society , Medical Oncology , All Patients Treated , Metastatic Head , Priming Immune Response Followed , Strategic Collaboration , Cancer Center , Validate Tumor Agnostic , Combination Agnostic Therapeutic , American Association , Cancer Research , Pancreatic Cancer , Cash Equivalents , Full Year , United States Food , Fast Track , Euronext Paris , Nasdaq Global Select Market , New York City , Private Securities Litigation Reform Act , Markets ,